TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: FlowTriever Pulmonary Embolectomy Clinical Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical signs, symptoms and presentation consistent with acute PE~* PE symptom duration ≤ 14 days~* CTA evidence of proximal PE~* RV/LV ratio ≥ 0.9 without syncope~* Systolic BP ≥ 90 mmHg~* Stable heart rate \<130 BPM prior to procedure~* Patient deemed medically eligible for interventional procedure(s), per institutional guidelines and/or clinical judgment~Exclusion Criteria:~* Thrombolytic use within 30 days of baseline CTA~* Pulmonary hypertension with peak PAP \> 70 mmHg by right heart catheterization~* Vasopressor requirement after fluids to keep pressure ≥ 90 mm Hg~* FiO2 requirement \> 40% or \> 6 LPM to keep oxygen saturation \> 90%~* Hematocrit \< 28% within 6 hours of index procedure~* Platelets \< 100,000/µL~* Serum creatinine \> 1.8 mg/dL~* INR \> 3~* Major trauma ISS \> 15~* Presence of intracardiac lead in right ventricle or atrium placed within 6 months~* Cardiovascular or pulmonary surgery within last 7 days~* Actively progressing cancer~* Known bleeding diathesis or coagulation disorder~* Left bundle branch block~* History of severe or chronic pulmonary arterial hypertension~* History of chronic left heart disease with left ventricular ejection fraction ≤ 30%~* History of uncompensated heart failure~* History of underlying lung disease that is oxygen-dependent~* History of chest irradiation~* History of Heparin-induced thrombocytopenia~* Any contraindication to systemic or therapeutic doses of heparin or anticoagulants~* Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated~* Imaging evidence or other evidence that suggests the subject is not appropriate for mechanical thrombectomy intervention~* Life expectancy of \< 90 days~* Female who is pregnant or nursing~* Current participation in another investigational drug or device treatment study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FlowTriever System (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phenytoin and Multidose Activated Charcoal

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Phenytoin level \> 30 mg/L~Exclusion Criteria:~* Age \< 18~* Known allergy to Activated Charcoal~* Pregnant~* Inability to take PO drugs~* Non English speaking~* Inability to give consent~* Any prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multiple Doses of Activated Charcoal (Type: EXPERIMENTAL): Patients will receive 50 grams of activated charcoal by mouth every 4 hours until phenytoin levels drop below 25 ug/cc
- Control (Type: NO_INTERVENTION): Will not receive activated charcoal. Serum levels will be followed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging and Treatment Studies of the Night Eating Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* men and women suffering from NES~* ages 18 to 70 years~* BMI greater than 18.5 kg/m2~Exclusion Criteria:~* Children or adolescents \<18 years~* persons older than 70~* patients with diabetes mellitus~* thyroid disease and other endocrine and metabolic disorders~* use within the past month of any psychotropic medication, oral steroids, diuretics or hypnotics~* current anorexia nervosa or bulimia nervosa~* participation in an organized weight reduction program~* use of antiobesity medication~* an occupation that involves night shifts or other unusual time requirements -Major Depressive Disorder (judged severe)~* Bipolar Disorder~* suicidal risk~* current or past psychosis~* substance use or abuse disorder within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Night Eaters (Type: EXPERIMENTAL): Subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing. For women, a pregnancy test will also be administered no more than 48 hours before SPECT-CT imaging and the beginning of escitalopram oxalate (Lexapro) treatment. Escitalopram oxalate (Lexapro) open-label treatment will last 12 weeks. Dosing will start at 10 mg and increase to 20 mg per day flexibly. Treatment will be discontinued starting at 12 weeks under the supervision of our study physician.
- Control Subjects (Type: NO_INTERVENTION): At the beginning of the study, control subjects will be given a medical history, height and weight will be measured, and BMI calculated. Initial outpatient assessment will include diary measurement of food intake and nighttime awakenings (and associated food intake) together with psychological testing.~An ADAM SPECT or SPECT-CT study of SERT binding will be conducted which will compare SERT binding of the 10 control subjects with that of the 30 night eating subjects. The first procedure will be to assess SPECT or SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin B Complex and Diabetic Nephropathy in Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type 1 diabetes.~* Patients aged 12-18 years with at least 5 years disease duration.~* Active diabetic nephropathy in the form of microalbuminuria (urinary albumin excretion \[UAE\] 30-299 mg/g creatinine in two of three samples over a 3- to 6- months period despite angiotensin converting enzyme inhibitors)~* Hemoglobin A1c (HbA1c) ≤8.5%~* Patients on regular visit to clinic.~* Patients on regular insulin therapy.~Exclusion Criteria:~Patients were excluded if they have any of the following:~* Patients with history of liver disease or any disorder likely to impair liver functions or elevated liver enzymes.~* Patients with any evidence of renal impairment due to cause other than diabetes.~* Patients with hypertension.~* Hepatitis virus infection (B or C) or any evidence of infection.~* Taking any vitamins or food supplements one month before study.~* Participation in a previous investigational drug study within 3 months preceding screening.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- intervention group (Type: ACTIVE_COMPARATOR): Intervention group included pediatric patients with diabetic nephropathy receiving oral vitamin B complex tablets( Neurorubine TM -Forte Lactab TM ) once daily.
- Control group (Type: PLACEBO_COMPARATOR): Placebo group or control patients received placebo that were similar in appearance to vitamin B complex tablets and the administered dose was as the same schedule as vitamin B complex .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Versus Dexmedetomidine as Adjuvants for Nerve Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age between 18 and 75 years~* American Society of Anesthesiologists classification 1-3~* body mass index between 20 and 35~Exclusion Criteria:~* adults who are unable to give their own consent~* pre-existing neuropathy (assessed by history and physical examination)~* coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)~* renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)~* hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)~* allergy to local anesthetics (LAs)~* pregnancy~* prior surgery in the infraclavicular region~* chronic pain syndromes requiring opioid intake at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Perineural dexamethasone (Type: ACTIVE_COMPARATOR): addition of dexamethasone to local anesthetics in infraclavicular brachial plexus block
- Perineural dexmedetomidine (Type: ACTIVE_COMPARATOR): addition of dexmedetomidine to local anesthetics in infraclavicular brachial plexus block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION CRITERIA:~In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the Exclusion criteria.~1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new~2. Planned or completed coronary angiogram for potential intervention~3. Age\>21~EXCLUSION CRITERIA:~* Inability to give informed consent~* Pregnancy~* Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)~* Preexisting severe left ventricular dysfunction (EF\<20%)~* Preexisting severe valvular heart disease~* Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with undetectable RNA~* Recent (\<14 days) or active use of anti-inflammatory drugs (not including non-steroidal anti-inflammatory drugs \[NSAIDs\] or corticosteroids used for IV dye allergy only)~* Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)~* Active malignancy - excluding carcinoma in situ \[any organ\] and non-melanoma skin cancer~* Anticipated need for cardiac surgery~* Neutropenia (absolute neutrophil count\<1,800/mm3)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Anakinra (standard dose) (Type: EXPERIMENTAL): Anakinra 100 mg daily for 14 days
- Anakinra (high dose) (Type: EXPERIMENTAL): Anakinra 100 mg twice daily for 14 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Top Down Versus Step Up Strategies in Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 16 - 75 years~* diagnosis of Crohn's disease within the past 4 years~* no previous treatment with corticosteroids, antimetabolites, or biologic agents.~* Active Crohn's disease, defined by a Crohn's Disease Activity Index (CDAI)20 score of greater than 200 points for a minimum of 2 weeks prior to randomization.~Exclusion Criteria:~* immediate need for surgery~* symptomatic stenosis or ileal/colonic strictures with prestenotic dilatation;~* signs, symptoms or laboratory tests indicating severe, medical disease;~* documented chronic infection~* a positive stool culture for pathogens~* a positive tuberculin test or a chest radiograph consistent with tuberculosis.~* malignancy~* allergy to murine proteins~* pregnancy~* substance abuse

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients received three infusions of infliximab 5 milligrams per kilogram (weeks 0, 2 and 6) in combination with azathioprine 2-2.5 milligrams per kilogram per day from day 0 onwards. If the patients responded and tolerated both drugs, azathioprine was continued for the duration of the trial. Patients who were intolerant to azathioprine received methotrexate at an initial dose of 25 milligrams administered subcutaneously each week for 12 weeks with dose reduction to 15 milligrams per week thereafter. Following initial therapy, patients who developed worsening symptoms were retreated with additional infusions of infliximab. If symptoms persisted methylprednisolone was initiated and azathioprine or methotrexate was continued.
- 2 (Type: ACTIVE_COMPARATOR): Induction with methylprednisolone (MP) or budesonide (BUD): MP 32 mg/day for 3 weeks was followed by tapering by 4 mg per week to 0; BUD 9 mg per day for 8 weeks with tapering to 0 by 3 mg per week thereafter.Patients who worsened during the tapering had the dose increased to the initial dose and tapered again. If patients worsened, azathioprine (2-2.5 mg per day) was introduced. Patients who relapsed following withdrawal of steroids received a second course in combination with azathioprine. For patients who failed 4 weeks of steroids, MP dose was given at 64 mg/day for 2 weeks, tapered by 8 mg per week; azathioprine was added. Patients who remained symptomatic despite 16 weeks of azathioprine received infliximab (5 mg/kg IV at weeks 0, 2 and 6). Patients who relapsed despite methotrexate or those intolerant to both azathioprine and methotrexate also received infliximab, without antimetabolite therapy. Infliximab was repeated upon relapse of symptoms in these patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients after elective craniotomy, requiring hyperosmolar agents for prevention or treatment of brain edema~Exclusion Criteria:~* age younger than 18 yr or older than 65 yr~* history of diabetes~* unstable hemodynamic condition~* presence of renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mannitol (Type: EXPERIMENTAL): 20% mannitol solution, 125 ml, IV infusion in 15 min
- Hypertonic saline (Type: EXPERIMENTAL): 3.1% sodium chloride solution, 125 ml, IV infusion in 15 min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Apart from benign non-toxic goiter no other serious illness~* Signed proof of participation~Exclusion Criteria:~* Treatment with Levothyroxine~* Former 131I-therapy~* A thyroid volume above 100 ml or a retro-clavicular component~* Unsafe contraception~* Pregnancy or breastfeeding~* Participation in another clinical trial~* Previous allergic reaction toward rhTSH~* Suspicion of malignancy in the thyroid gland either by clinical examination, laboratory findings (a raised serum calcitonin or ionized calcium)or by fine-needle aspiration biopsy~* Physically or mental condition making it impossible to participate~* Acute ischemic heart attach within the last 3 months~* Alcohol and/or drug addicts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhTSH (Type: ACTIVE_COMPARATOR): proceeded by 0.1 mg rhTSH
- Placebo (Type: PLACEBO_COMPARATOR): 1 ml isotonic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria for subjects:~* Completed 24-weeks of study treatment as described in the core protocol (CICL670F2201).~* Were deemed to have tolerated deferasirox treatment by the investigator.~* Provided written informed consent/assent before any study-specific procedures were performed. For pediatric patients, consent was obtained from parent(s) or legal patient's representative. Investigators were to have also obtained assent of patients according to local, regional or national guidelines.~Key Exclusion for subjects:~The exclusion criteria followed those described for the core protocol CICl670F2201, which were as follows:~* Creatinine clearance below the contraindication limit in the locally approved prescribing information.~* Serum creatinine \> 1.5 × upper limit of normal range (ULN) at Screening~* Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) \> 5 × ULN,~* Significant proteinuria~* Patients with significant impaired gastrointestinal function or gastrointestinal disease~* Clinical or laboratory evidence of active Hepatitis B or Hepatitis C~* Patients with psychiatric or addictive disorders~* Patients with a known history of HIV seropositivity (Elisa or Western blot).~* History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there was an evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin.~* Patients with a history of hypersensitivity to any of the study drug or excipients.~* Patients with significant medical condition that could interfere with the ability to participate in this study~* Patients who were participating in another clinical trial or receiving an investigational drug.~* Patients using prohibited medication,~* Patients with liver disease with severity of Child-Pugh Class B or C.~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they were using effective methods of contraception during dosing of study treatment

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox (Type: EXPERIMENTAL): Treatment will be administered daily for up to 24 months. For each patient the daily dose is calculated based on the patient's actual body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tizanidine and Pain After Herniorrhaphy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologist's physiologic state I-III patients undergoing unilateral inguinal herniorrhaphy~Exclusion Criteria:~* chronic pain~* bleeding disorders~* renal or hepatic insufficiency~* patients on chronic non-steroidal anti-inflammatory medications~* recurrent hernias~* emergency cases

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tizanidine (Type: EXPERIMENTAL): Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
- Placebo (Type: PLACEBO_COMPARATOR): Group Placebo (Group P) will receive placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete